share_log

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences公司宣佈，它已經在Arc-10中給第一個受試者注射了劑量，這是一個第三階段的研究，公司説，第一個受試者的劑量將觸發向藥明生物和Abmuno治療公司支付1000萬美元的里程碑式的付款
Benzinga Real-time News ·  2021/03/17 04:32

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences公司宣佈，它已經在Arc-10中給第一個受試者注射了劑量，這是一個第三階段的研究，公司説，第一個受試者的劑量將觸發向藥明生物和Abmuno治療公司支付1000萬美元的里程碑式的付款

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論